Avail Scientific Signs LOI to Acquire Florida Neurological Testing Company Relai Neuro
Avail Scientific (OTC PINK: MOBO) has signed a letter of intent to acquire Relai Neuro LLC, a Florida-based company specializing in neurological testing and data management. This acquisition aims to double Relai's sales force within three months and expand services into California, Texas, and Colorado. According to CEO Dr. James Thompson, the collaboration will enhance offerings and facilitate market expansion. Avail's CEO, Michael Paul, emphasizes that this acquisition will support their goal of leading in clinically studied psychedelic therapeutics for addiction and mental health, particularly through innovative methodologies for measuring treatment outcomes.
- Acquisition of Relai Neuro will double sales force within three months.
- Expansion into California, Texas, and Colorado markets.
- Bolsters Avail's offerings in psychedelic therapeutics for addiction treatment.
- None.
TORONTO, ON / ACCESSWIRE / January 19, 2023 / AVAIL SCIENTIFIC (OTC PINK:MOBO) is pleased to announce it is entering into a letter of intent (LOI) to acquire Florida based Relai Neuro LLC which provides Neurological testing and data management.
This acquisition will allow Relai to double its sales force over the next three months as well as expand services into California, Texas, and Colorado.
Dr. James Thompson, CEO of Relai Neuro, says; "We are excited to work with Avail Scientific. The acquisition will allow us to bolster our offerings and our team. Additionally, the acquisition of Relai will allow us to achieve our goals of expansion in Florida, as well as expand quickly into California, Texas, and Colorado markets."
"Relai Nero allows Avail to continue to accelerate our treatment applications, testing and supporting data collection as we strive to become a world leader in the clinically studied and supported use of psychedelic therapeutics for treatment of addiction & mental health issues," says Avail CEO, Michael Paul.
Relai Neuro provides neurological testing and data management to rehab and mental health treatment centres in Florida.
Relai's products and methodology allow for the direct measurement of progress in neural functions of patients under various treatments. For example, Relai is currently measuring the effects of Psilocybin micro-dosing on addiction in patients within a clinical environment.
RelaiNeuro - https://nusqu.com/relaineuro
About Avail Scientific
Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse.
We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally.
Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.
Contact:
SOURCE: Mobile Lads, Corp.
View source version on accesswire.com:
https://www.accesswire.com/735873/Avail-Scientific-Signs-LOI-to-Acquire-Florida-Neurological-Testing-Company-Relai-Neuro
FAQ
What does Avail Scientific's acquisition of Relai Neuro entail?
How will the acquisition of Relai Neuro benefit Avail Scientific?
What markets will Avail Scientific expand into with Relai Neuro's acquisition?
What is the significance of Relai Neuro's testing methodology?
What is Avail Scientific's main focus after acquiring Relai Neuro?
